Journal
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 159, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejps.2021.105730
Keywords
C-terminal lysine clipping; charge variants; Fc gamma RIIIa; FcRn; affinity chromatography; surface plasmon resonance; mass spectrometry; monoclonal antibody
Categories
Funding
- LFB Biotechnologies
Ask authors/readers for more resources
Research shows that the C-terminal lysine clipping of monoclonal antibodies does not have a significant impact on their ability to bind human Fc receptors, resulting in comparable biological properties.
Monoclonal antibodies (mAbs) display numerous structural attributes, some of them may impact their safety and/or efficacy profiles. C-terminal lysine clipping is a common phenomenon occurring during the bioproduction of mAbs and leads to variable amounts of final process-related charge variants. If Fc-glycosylation has been by far the most documented critical quality attribute (CQA), the potential impacts of mAb C-terminal lysine content is far less reported, particularly on the ability of these basic variants to bind human Fc receptors. To address this question, three charge variant species having zero (K0), one (K1) and two (K2) C-terminal lysine(s) were isolated with high purity from an in-house human IgG1 by preparative strong-cation exchange (SCX) chromatography. A comprehensive biophysical characterization of these three fractions was undertaken, demonstrating their high similarity in terms of structural homogeneity, with a particular attention paid on their respective N-glycosylation profiles. The binding affinity of the fractions to human Fc gamma RIIIa-Val(176) was assessed both by affinity chromatography and surface plasmon resonance (SPR), and to human neonatal Fc receptor (FcRn) by affinity chromatography. Results demonstrate that the three charge variants did not show any significant binding difference for the two tested human Fc receptors, translating certainly to comparable biological properties. As a consequence, C-terminal lysine clipping of the present therapeutic IgG1 should not impact both FcRn-dependent pharmacokinetic profiles and Fc gamma RIIIa-driven cytotoxic activities. The methods used in this study can be widely applied to other IgG1 to define criticality of the C-terminal lysine clipping as a CQA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available